Creating a tool to predict treatment responses in acute myeloid leukemia patients
Development of a Phenotype-based Predictive Analytic for Acute Myeloid Leukemia
This study is looking to help people with relapsed acute myeloid leukemia (AML) by testing a new combination of medicines to see who might benefit the most from them, using special techniques to understand their unique cells better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-11085055 on NIH RePORTER |
What this research studies
This research focuses on improving treatment outcomes for patients with relapsed and refractory acute myeloid leukemia (AML) by developing a predictive analytic tool. The study involves a collaboration between Vanderbilt University Medical Center and industry partners to test a combination therapy using venetoclax and selinexor. By utilizing advanced flow cytometry techniques, the research aims to identify which patients are likely to respond to this treatment based on their unique cellular characteristics. This approach seeks to personalize therapy and enhance the effectiveness of existing treatments for AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with relapsed or refractory acute myeloid leukemia who have not responded to standard treatments.
Not a fit: Patients with newly diagnosed acute myeloid leukemia or those who are not experiencing relapse may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with difficult-to-treat AML, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in using combination therapies for AML, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Savona, Michael R — Vanderbilt University Medical Center
- Study coordinator: Savona, Michael R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.